Stock Financial Ratios, Dividends, Split History

ROSE / Rosehill Resources Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)47.25
Enterprise Value ($M)212.70
Book Value ($M)29.11
Book Value / Share4.53
Price / Book1.70
NCAV ($M)-261.31
NCAV / Share-40.65
Price / NCAV-0.18
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 5,945,000
Common Shares Outstanding 6,222,299
Weighted Average Number Of Shares Outstanding Basic 5,945,000
Common Shares Outstanding2 29,807,692
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.10
Return on Assets (ROA)-0.14
Return on Equity (ROE)-2.39
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio0.40
Income Statement (mra) ($M)
Oil And Gas Sales Revenue61,596,000.00
Natural Gas Production Revenue7,171,000.00
Oil And Condensate Revenue7,469,000.00
Sales Revenue Net76,236,000.00
Revenue Receivable Current0.00
Operating Income8.89
Net Income-11.95
Earnings Per Share Diluted-1.43
Earnings Per Share Basic And Diluted-1.43
Earnings Per Share Basic-1.43
Cash Flow Statement (mra) ($M)
Cash From Operations37.76
Cash from Investing-265.50
Cash from Financing-265.50
Identifiers and Descriptors
Central Index Key (CIK)1659122
Industry Groups

Split History

Stock splits are used by Rosehill Resources Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

Rosehill Resources' (ROSE) CEO Alan Townsend on Q1 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Good day, ladies and gentlemen and welcome to the Rosehill Resources' First Quarter 2018 Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, today's program maybe recorded. (1-0)

Fifth Third's (FITB) Q1 Earnings & Revenues Beat Estimates

2018-04-24 zacks
Have you been eager to see how Fifth Third Bancorp (FITB - Free Report) performed in Q1 in comparison with the market expectations? Let’s quickly scan through the key facts from this Ohio-based bank’s earnings release this morning: An Earnings Beat Fifth Third came out with adjusted earnings per share of 57 cents, surpassing the Zacks Consensus Estimate of 48 cents. The figure excludes the net positive impact of gain from the Vantiv merger with WorldPay and charges related to the valuation of the Visa total return swap and adjustment to litigation reserves. (72-0)

Can The Uptrend Continue for Rosehill Resources (ROSE)?

2018-04-23 zacks
Investors certainly have to be happy with Rosehill Resources Inc. (ROSE - Free Report) and its short term performance. After all, the stock has jumped by 23.3% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for ROSE? (8-0)

Construct Your Oil Portfolio: The Capital Appreciation Version

2018-04-23 seekingalpha
This is Part 3 of a three-piece series aiming to take a long, hard look at how to go about building an oil stock portfolio that fits your personality. (20-1)

Rosehill Resources Inc. 2017 Q4 - Results - Earnings Call Slides

2018-04-19 seekingalpha
The following slide deck was published by Rosehill Resources Inc. in conjunction with their 2017 Q4 earnings call. (1-0)

CUSIP: 777385105